To include your compound in the COVID-19 Resource Center, submit it here.

Aegerion endocrine/metabolic news

Aegerion said it resolved a warning letter from FDA's Office of Prescription Drug Promotion regarding statements CEO Marc Beer

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE